NAFLD is the hepatic manifestation of metabolic syndrome (MetS); as such, any treatment of proven efficacy of MetS is alos expected to improve hepatic steatosis. The presence of fat in the liver is, per se, evidence of increased cardiovascular risk, independent of a variety of classical risk factors and the presence of MetS itself. Innovative drug treatments, specifically acting on pathogenic mechanisms of lipid accumulation and glucose regulation are on the horizon.
Managing the combination of nonalcoholic fatty liver disease and the metabolic syndrome
Moscatiello S;Di Luzio R;Sasdelli AS;
2011
Abstract
NAFLD is the hepatic manifestation of metabolic syndrome (MetS); as such, any treatment of proven efficacy of MetS is alos expected to improve hepatic steatosis. The presence of fat in the liver is, per se, evidence of increased cardiovascular risk, independent of a variety of classical risk factors and the presence of MetS itself. Innovative drug treatments, specifically acting on pathogenic mechanisms of lipid accumulation and glucose regulation are on the horizon.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
